News

MAP Pharmaceuticals (MAP) has completed a planned interim safety review of the open-label, long-term safety extension of its phase 3 FREEDOM 301 clinical trial, with its Levadex orally

Novartis has shipped over 7.5 million doses of Influenza A(H1N1) vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in

Market research firm, Mintel has reported that because of the outbreak of H1N1 (swine flu), people around the world are flocking to drugstores and supermarkets to stock up

Cumberland Pharmaceuticals (Cumberland) and Phebra have entered into an exclusive partnership for the commercialization of Caldolor (ibuprofen) Injection in Australia and New Zealand. Caldolor, an intravenous formulation of

The FDA has issued a Complete Response Letter to Transcept Pharmaceuticals (Transcept) regarding the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet). The NDA, submitted by

Roche has released the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research. The

Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake

MasterControl and i4DM have been selected as the software provider and implementation team of a quality management system (QMS) for the Food and Drug Administration (FDA). The FDA’s

Banner Pharmacaps has signed an agreement with Midway Importing for the exclusive marketing and distribution of its Gelcaps Primero la Familia product line in the US. Banner’s Gelcaps